Emma Scott

Trials

Studies that name Emma Scott as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:11 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03499808 · S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  SWOG Cancer Research Network · completed · Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea · principal investigator
• Ph1
  NCT01689987 · Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

  OHSU Knight Cancer Institute · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 00:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT03499808
• Cancer Center Administration
  P30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mindy Roberts · fiscal years 2004 to 2026
  Named on NCT01689987